Drug intelligence / Profile preview

TEV-279

Development stage: Preclinical
Lead developer: Teva Pharmaceutical Industries

Overview

TEV-279 is an early-stage investigational drug candidate being developed by Teva Pharmaceuticals. It is currently in the preclinical stage of development, specifically targeting indications within the neuroscience therapeutic area. As a preclinical asset, specific details regarding its molecular target, mechanism of action, and exact modality have not been publicly disclosed by the developer. The program is part of Teva's broader research and development efforts to expand its innovative pipeline in central nervous system disorders.

Beyond the preview

Go deeper on TEV-279.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEV-279.

Explore the full profile